Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor

Frontiers in Pediatrics

Luisa Santoro¹  Antonella Facchinetti²  Elisabetta Rossi²  Lucia Tombolan³  Gianni Bisogno³  Maria Carmen Affinita³  Paolo Bonvini⁴  Angelica Zin⁴  Rita Zamarchi⁵  Riccardo Vidotto⁵  Mariangela Manicone⁵ 

[1] Department of Medicine, Padova University Hospital, Padova, Italy;Department of Surgery, Oncology and Gastroenterology, Oncology Section, University of Padova, Padova, Italy;Veneto Institute of Oncology IOV - IRCCS, Padova, Italy;Hematology and Oncology Unit, Department of Women's and Children's Health, University of Padova, Padova, Italy;Institute of Pediatric Research, Fondazione Città della Speranza, Padova, Italy;Veneto Institute of Oncology IOV - IRCCS, Padova, Italy;

关键词: IMT;    ALK;    CTC;    metastasis;    CellSearch;    liquid biopsy;   

DOI  :  10.3389/fped.2021.652583

来源: Frontiers

【 摘 要 】

Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis is generally good. For children with unresectable or metastatic tumors, however, outcome is particularly severe, limited also by the lack of predictive biomarkers of therapy efficacy and disease progression. Blood represents a minimally invasive source of cancer biomarkers for real-time assessment of tumor growth, particularly when it involves the analysis of circulating tumor cells (CTC). As CTCs potentially represent disseminated disease, their detection in the blood correlates with the presence of metastatic lesions and may reflect tumor response to treatment. Herein, we present a case report of a 19-year-old boy with an ALK-positive IMT of the bladder, proximal osteolytic and multiple bilateral lung lesions, who received ALK inhibitor entrectinib postoperatively and underwent longitudinal CTC analysis during treatment. Antitumor activity of entrectinib was demonstrated and was accompanied by regression of lung lesions, elimination of CTCs from the blood and no development of relapses afterwards. Therapy continued without any clinical sign of progression and 24 months since the initiation of treatment the patient remains symptom-free and disease-free.

【 授权许可】

CC BY